Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089720 | 0.86 | ALDH1A1 (0.41) | L3MBTL1POLBKDM4EALDH1A1ALOX15 | |
| SCHEMBL21795445 | 0.81 | KDM4E (0.42) | L3MBTL1POLBKDM4EALDH1A1ALOX15 | |
| SCHEMBL6918629 | 0.78 | TSHR (0.44) | L3MBTL1POLBKDM4EALDH1A1ALOX15 | |
| SCHEMBL12017936 | 0.78 | — | — | |
| SCHEMBL16478641 | 0.76 | KDM4E (0.36) | L3MBTL1POLBNPSR1KDM4EALDH1A1 | |
| SCHEMBL20690599 | 0.76 | KDM4E (0.40) | L3MBTL1POLBNPSR1KDM4EALDH1A1 | |
| SCHEMBL16472414 | 0.76 | KDM4E (0.36) | L3MBTL1POLBNPSR1KDM4EALDH1A1 | |
| SCHEMBL2551331 | 0.75 | POLB (0.49) | L3MBTL1POLBNPSR1KDM4EALDH1A1 | |
| SCHEMBL25341665 | 0.74 | KDM4E (0.32) | L3MBTL1POLBNPSR1KDM4EALDH1A1 | |
| SCHEMBL23163847 | 0.74 | KDM4E (0.32) | L3MBTL1POLBNPSR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394068-A1 | TDO2 INHIBITORS | Genentech, Inc. (US) | 2018-10-31 | — | — | EP | claimed |
| US-20180134713-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | LILLY CO ELI (US) | 2018-05-17 | — | — | US | claimed |
| EP-3310781-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | Eli Lilly and Company (US) | 2018-04-25 | — | — | EP | claimed |
| CN-107660206-A | For preparing the method and intermediate of { base of 1 (ethylsulfonyl) 3 [base of 4 (base of 7H pyrrolo-es [2,3 d] pyrimidine 4) 1H pyrazoles 1] azetidine 3 } acetonitrile | 伊莱利利公司 | 2018-02-02 | — | — | CN | claimed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| WO-2016205487-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | ELI LILLY AND COMPANY (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |
| CN-119059953-A | Method for rapidly synthesizing 1- (ethylsulfonyl) azetidin-3-one | 吉林大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-118852104-A | Dihydro-quinoline-2-ketone compound and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-10800775-B2 | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | ACLARIS THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190135807-A1 | PYRAZOLYL PYRROLO[2,3-B]PYRMIDINE-5-CARBOXYLATE ANALOGS AND METHODS OF MAKING THE SAME | ACLARIS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20180134713-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | LILLY CO ELI (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134713-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | LILLY CO ELI (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3310781-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | Eli Lilly and Company (US) | 2018-04-25 | — | — | EP | disclosed |
| CN-107660206-A | For preparing the method and intermediate of { base of 1 (ethylsulfonyl) 3 [base of 4 (base of 7H pyrrolo-es [2,3 d] pyrimidine 4) 1H pyrazoles 1] azetidine 3 } acetonitrile | 伊莱利利公司 | 2018-02-02 | — | — | CN | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2016205487-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | ELI LILLY AND COMPANY (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205487-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | ELI LILLY AND COMPANY (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135807-A1 | PYRAZOLYL PYRROLO[2,3-B]PYRMIDINE-5-CARBOXYLATE ANALOGS AND METHODS OF MAKING THE SAME | JAK3, JAK1, JAK2 | L3MBTL1 3275/4885POLB 1224/4885NPSR1 3767/4885 |
| US-20180134713-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | AZI2, SRMS, ABL1 | L3MBTL1 4685/4885POLB 1300/4885NPSR1 3409/4885 |
| US-10800775-B2 | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | JAK3, JAK1, JAK2 | L3MBTL1 3275/4885POLB 1224/4885NPSR1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.